Hellemans P, van Dam P A, Weyler J, van Oosterom A T, Buytaert P, Van Marck E
Department of Obstetrics and Gynaecology, Antwerp University Hospital, Edegem, Belgium.
Br J Cancer. 1995 Aug;72(2):354-60. doi: 10.1038/bjc.1995.338.
Expression of the bcl-2 proto-oncogene was studied immunohistochemically in 251 invasive ductal breast carcinomas (median follow-up time 91 months, range 24-186 months) and the results were correlated with clinicopathological data and prognostic variables. Sixty-three (25%) tumours were scored bcl-2 negative and 188 (75%) tumours were bcl-2 positive. No relationship could be observed between bcl-2 status and tumour grade, pTNM staging or menopausal status. A strong positive relationship was demonstrated between bcl-2 immunoreactivity and oestrogen receptor status (P < 0.001) and progesterone receptor status (P < 0.001). No prognostic value was demonstrated for bcl-2 expression on disease-free survival and overall survival in axillary node-negative breast cancer patients. However, in axillary node-positive breast cancer patients multivariate analysis demonstrated absence of bcl-2 expression to be independently related to shortened disease-free survival (P = 0.003) and shortened overall survival (P < 0.001). Our results suggest a potential important role for bcl-2 expression as a modulator of response to adjuvant therapy in breast cancer.
采用免疫组织化学方法研究了251例浸润性导管乳腺癌（中位随访时间91个月，范围24 - 186个月）中bcl-2原癌基因的表达情况，并将结果与临床病理数据及预后变量进行了相关性分析。63例（25%）肿瘤bcl-2表达阴性，188例（75%）肿瘤bcl-2表达阳性。未观察到bcl-2状态与肿瘤分级、pTNM分期或绝经状态之间存在关联。bcl-2免疫反应性与雌激素受体状态（P < 0.001）和孕激素受体状态（P < 0.001）之间呈强正相关。在腋窝淋巴结阴性的乳腺癌患者中，未证明bcl-2表达对无病生存期和总生存期具有预后价值。然而，在腋窝淋巴结阳性的乳腺癌患者中，多因素分析表明bcl-2表达缺失与无病生存期缩短（P = 0.003）和总生存期缩短（P < 0.001）独立相关。我们的结果提示bcl-2表达作为乳腺癌辅助治疗反应的调节因子可能具有重要作用。
